BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...expertise silos,” said Aranout. -- Karen Tkach Tuzman AZ’s diabetes portfolio contains marketed GLP-1R and amylin receptor...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

...cotransporter 1 (SGLT1) Glucose signaling pathway Not expected LX2761 Small molecule Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Amylin receptor...
BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...he said. Lilly has a about dozen clinical-stage programs in its diabetes pipeline targeting the amylin receptor...
BioCentury | Jun 23, 2017
Company News

KeyBioscience grants Lilly rights to Type II diabetes platform

...Denmark Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic Alicia Parker Eli Lilly and Co. Nordic Bioscience A/S Amylin receptor Calcitonin...
BioCentury | Aug 20, 2012
Company News

Unigene musculoskeletal news

...to treat obesity. The company had planned to start Phase I testing of the anorexigenic amylin receptor...
BioCentury | Aug 8, 2011
Clinical News

Pramlintide/Metreleptin: Development discontinued

...Diego, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Pramlintide/Metreleptin Business: Endocrine Molecular target: Amylin receptor...
BioCentury | Jul 18, 2011
Clinical News

Unigene preclinical data

...meeting in San Diego. Unigene plans to start a Phase I trial of the anorexigenic amylin receptor...
BioCentury | Mar 21, 2011
Clinical News

Pramlintide/metreleptin: Phase II halted

...Diego, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Pramlintide/metreleptin Business: Endocrine Molecular target: Amylin receptor...
BioCentury | Feb 17, 2011
Distillery Therapeutics

Indication: Endocrine disease

...Next steps include identifying brain-penetrating LRP1 agonists. Amylin Pharmaceuticals Inc. has a coformulation of the amylin receptor...
BioCentury | Jul 12, 2010
Clinical News

Symlin pramlintide acetate: Post-marketing study data

...Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), San Diego, Calif. Product: Symlin pramlintide acetate Business: Endocrine Molecular target: Amylin receptor...
Items per page:
1 - 10 of 37